Welcome to our dedicated page for Champions Oncolo news (Ticker: CSBR), a resource for investors and traders seeking the latest updates and insights on Champions Oncolo stock.
Champions Oncology, Inc. reports developments as a translational oncology research organization serving biopharma drug discovery and development. The company’s updates center on preclinical and clinical research services, patient-derived xenograft (PDX) and primary hematological malignancy models, proprietary in vivo and ex vivo platforms, bioanalytical capabilities, and data services that connect tumor models with molecular and clinical datasets.
Recurring news themes include quarterly operating results, study service revenue, bookings and backlog conversion, data platform investment, research presentations at oncology meetings, and governance changes. Company research updates describe model-based studies of therapeutic response, resistance, biomarkers, and tumor biology across oncology development programs.
Champions Oncology, Inc. (NASDAQ:CSBR) announced a partnership with Code Ocean on January 19, 2021, aimed at enhancing its Lumin Bioinformatics SaaS program. The collaboration focuses on improving data integration and sharing workflows, allowing users to centralize their code and data securely. This enhancement positions Lumin as an enterprise-level solution, broadening its market potential. The partnership addresses unstructured data within research centers, aiming to turn Lumin into a foundational tool for oncology research.
Champions Oncology (NASDAQ:CSBR) announced the expansion of its Lumin Bioinformatics program, which now includes over 20,000 datasets, enhancing its proteomic data capabilities. This initiative aims to provide researchers with advanced analysis tools to better understand tumor biology and therapeutic resistance. The integration of proteomics into Lumin allows for direct insights into protein expression, moving beyond traditional RNA and DNA sequencing methods. Key executives highlighted the potential of this expanded dataset to transform cancer research and improve data accessibility for scientists.
Champions Oncology (NASDAQ:CSBR) announced record quarterly revenue of $10.1 million for Q2 fiscal 2021, a 33% increase year-over-year. The company launched its proprietary Lumin Bioinformatics SaaS platform, enhancing drug discovery capabilities. Income from operations, excluding stock-based compensation, was $400,000, although total operating expenses rose 37.9% to $10.1 million. The gross margin declined to 44.2% due to increased costs. The company raised its full-year revenue guidance to 20%-25%.
Champions Oncology, Inc. (CSBR) will report its financial and operational results for the second quarter on December 14, 2020, after market close. A conference call will be held at 4:30 p.m. EST to discuss the results. The company specializes in oncology technology solutions aimed at transforming drug discovery through advanced pharmacology and biomarker data platforms. Champions is noted for its innovative approach to personalizing cancer care with its Champions TumorGrafts technology.
Champions Oncology, Inc. (NASDAQ:CSBR) has launched its new proprietary SaaS program, Lumin Bioinformatics, aimed at enhancing drug discovery in oncology. Leveraging a unique and extensive cancer dataset, Lumin offers users a comprehensive database for tumor characterization combined with advanced analytic tools. This software subscription facilitates research into drug response, clinical annotations, and genetic dependencies. The launch aligns with the company's strategy to utilize its data to support biopharma organizations lacking large bioinformatic teams.
Champions Oncology, Inc. (CSBR) has launched a novel autologous immuno-oncology research platform, enhancing drug discovery. This tumor infiltrating lymphocyte (TIL) ex vivo platform uses a patient's tumor and immune system to aid immuno-oncology research. CEO Ronnie Morris highlighted its significance for biopharma, while CCO Michael Ritchie emphasized its unique capability for repeat studies, allowing deeper insights into immune-tumor interactions. The platform fills critical gaps in therapeutic development, fostering the creation of better oncology treatments.
Champions Oncology (NASDAQ:CSBR) reported record revenue of $9.5 million for the first fiscal quarter ending July 31, 2020, marking a 42% year-over-year increase. The company achieved income from operations of $421,000 excluding non-cash expenses, reflecting a significant improvement from a loss of $614,000 in the prior year. Operating expenses rose to $9.5 million, up 29.5% year-over-year. The firm ended the quarter with a strong cash position of $6.9 million and no debt, bolstering its long-term growth prospects.
Champions Oncology, Inc. (NASDAQ:CSBR) will release its first-quarter financial and operational results on September 14, 2020, after market close. A conference call is scheduled for 4:30 p.m. EDT on the same day to discuss these results. The call can be accessed by dialing 877-407-8035 domestically or 201-689-8035 internationally. The company specializes in technology solutions for oncology drug development, utilizing its platform to personalize cancer care and improve drug development processes. Further information is available on their website.